InvestSMART

Alcidion Group Limited (ASX:ALC)

ALERT: Price-sensitive ASX Announcement for ALC
Current share price for ALC : $0.100 0.013 (14.94%)+
Announcement
Release
19 Aug 2026 8:00AM
Price at Release
$0.087
Full Release
download
Summary
Alcidion Group Limited's FY26 results show strong financial performance with a 27% increase in revenue and significant contract wins and renewals. The company achieved a total revenue of $51.6 million, driven by a 21% increase in recurring revenue from new customer wins and expansions, particularly in the UK and Australia. Key highlights include the acquisition of Kyra flow products, which added 33 new customers and strengthened their leadership in the patient flow market. Alcidion reported a gross profit of $41.5 million and an EBITDA of $6.2 million, demonstrating improved operating leverage. The company maintains a strong balance sheet with $20.6 million in cash and no debt, allowing for further growth opportunities. Alcidion's strategy focuses on sustainable growth through long-term, contracted recurring revenue, particularly from their Miya Precision platform, which addresses critical healthcare challenges and enhances system interoperability.
Key Points
  • 27% increase in total revenue for FY26.
  • Successful acquisition of Kyra flow products from Telstra Health.
  • 21% increase in recurring revenue from new customer wins.
  • Revenue driven by significant contracts in the UK and Australia.
  • Gross profit reached $41.5 million with a 15% increase.
  • EBITDA reported at $6.2 million, a 28% increase from FY25.
  • Strong balance sheet with $20.6 million in cash and no debt.
  • Strategic focus on long-term, contracted recurring revenue.
  • Expansion of Miya Precision platform across healthcare systems.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.